Logo

Cadila to Launch its Ritucad (rituximab- biosimilar) in India

Share this

Cadila to Launch its Ritucad (rituximab- biosimilar) in India

Shots:

  • Cadila to strengthen its biosimilar portfolio and oncology footprints in India with the launch of Ritucad and has cleared USFDA inspection in Feb’20
  • Additionally- the company has launched its Bevaro (bevasizumab- biosimilar) a mAb targeted for multiple cancer indications like Ovarian Cancer- Glioblastoma Multiforme (a type of Brain cancer)- Colorectal Cancer- Breast Cancer- Lung Cancer- Cervical Cancer and Kidney Cancer in India
  • Ritucad is the second biosimilar in Cadila’s portfolio of biosimilars and will be available in a single-dose vial of two strengths- 100 mg & 500mg targeted to treat Non-Hodgkin’s lymphoma and RA

Ref: Cadila | Image: Twitter

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions